


AMENDMENTS TO THE CLAIMS

Please amend the claims according to the clean version and marked-up version of the claim listings provided below.

Clean version of the amended claims:

1. (original) A compound of Formula (I):



wherein:

R₁ is H or C₁₋₈ alkyl;
R₂ is C₁₋₄ alkyl, -CH₂-O-C₁₋₄ alkyl, C₁₋₄ haloalkyl or CH₂OH; and
R₃, R₄, R₅ and R₆ are each independently H, C₁₋₄ alkyl, amino, cyano, halogen, C₁₋₄ haloalkyl, nitro or OH; or
a pharmaceutically acceptable salt, hydrate and solvate thereof;
provided that when R₂ is C₁₋₄ alkyl, -CH₂-O-C₁₋₄ alkyl, and CH₂OH then
R₃ and R₆ are not both hydrogen.

2. (original) The compound according to claim 1 wherein R₁ is H.
3. (original) The compound according to claim 1 wherein R₁ is C₁₋₈ alkyl.

Claims 4 to 8 have been canceled.

9. (amended) The compound according to claim 1 wherein R₂ is C₁₋₄ alkyl.
10. (amended) The compound according to claim 1 wherein R₂ is methyl.

Claims 11 to 13 have been canceled.

14. (amended) The compound according to claim 1 wherein R_2 is C_{1-4} haloalkyl.

Claim 15 has been canceled.

16. (amended) The compound according to claim 1 wherein R_3 is H.

17. (amended) The compound according to claim 1 wherein R_3 is C_{1-4} alkyl.

Claims 18 to 20 have been canceled.

21. (amended) The compound according to claim 1 wherein R_3 is halogen.

Claims 22 to 25 have been canceled.

26. (amended) The compound according to claim 1 wherein R_3 is C_{1-4} haloalkyl.

Claims 27 to 29 have been canceled.

30. (amended) The compound according to claim 1 wherein R_4 is H.

31. (amended) The compound according to claim 1 wherein R_4 is C_{1-4} alkyl.

Claims 32 to 34 have been canceled.

35. (amended) The compound according to claim 1 wherein R_4 is halogen.

Claims 36 to 39 have been canceled.

40. (amended) The compound according to claim 1 wherein R_4 is C_{1-4} haloalkyl.

Claims 41 to 43 have been canceled.

44. (amended) The compound according to claim 1 wherein R_5 is H.

45. (amended) The compound according to claim 1 wherein R_5 is C_{1-4} alkyl.

Claims 46 to 48 have been canceled.

49. (amended) The compound according to claim 1 wherein R_5 is halogen.

Claims 50 to 53 have been canceled.

54. (amended) The compound according to claim 1 wherein R_5 is C_{1-4} haloalkyl.

Claims 55 to 57 have been canceled.

58. (amended) The compound according to claim 1 wherein R_6 is H.

59. (amended) The compound according to claim 1 wherein R_6 is C_{1-4} alkyl.

Claims 60 to 62 have been canceled.

63. (amended) The compound according to claim 1 wherein R_6 is halogen.

Claims 64 to 67 have been canceled.

68. (amended) The compound according to claim 1 wherein R_6 is C_{1-4} haloalkyl.

Claims 69 to 71 have been canceled.

72. (original) The compound of claim 1 selected from the group consisting of:
6,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
6-Chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
8-Chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and

8,9-Dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine.

73. (original) The compound of claim 1 that is 9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine.

74. (original) The compound of claim 1 selected from the group consisting of:
N-methyl-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine; and
N-methyl-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine.

75. (amended) The compound according to claim 1 wherein said compound is an *R* enantiomer.

76. (amended) The compound according to claim 1 wherein said compound is an *S* enantiomer.

77. (amended) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

78. (amended) A method of modulating a 5HT_{2C} receptor comprising contacting said receptor with a therapeutically effective amount of a compound according to claim 1.

79. (original) The method according to claim 78 wherein said compound is an agonist of said receptor.

80. (amended) A method of prophylaxis or treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus or sleep apnea comprising administering to an individual in need of such prophylaxis or treatment a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition according to claim 77.

81. (original) The method according to claim 80 wherein the disorders of the central nervous system are selected the group consisting of depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality

disorders, Alzheimer disease, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.

82. (original) The method according to claim 81 wherein the disorder of the central nervous system is obesity.

Claim 83 has been canceled.

84. (original) The method according to claim 81 wherein the sexual dysfunction is Male erectile dysfunction.

Claims 85 to 89 have been canceled.

90. (amended) The method according to claim 82 or 84 wherein said individual is a human.

91. (amended) A method of decreasing food intake of an individual comprising administering to said individual a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition according to claim 77.

Claim 92 has been canceled.

93. (amended) The method according to claim 91 wherein said individual is a human.

94. (amended) A method of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition according to claim 77.

Claim 95 has been canceled.

96. (amended) The method according to claim 94 wherein said individual is a human.

97. (amended) A method of controlling weight gain of an individual comprising administering to said individual suffering from weight control a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition according to claim 77.

Claim 98 has been canceled.

99. (amended) The method according to claim 97 wherein said individual is a human.

Claims 100 to 103 have been canceled.

104. (amended) A method of producing a pharmaceutical composition comprising admixing at least one compound according to claim 1 and a pharmaceutically acceptable carrier.


Claims 105 to 123 have been canceled.

124. (new) The compound according to claim 1 wherein:
R₁ is H, methyl, ethyl, *n*-propyl, *iso*-propyl or *n*-butyl;
R₂ is methyl, ethyl, *iso*-propyl, *n*-butyl or -CF₃;
R₃ is H, -CH₃, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF₃, nitro or -OH;
R₄ is H, -CH₃, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF₃, nitro or -OH;
R₅ is H, -CH₃, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF₃, nitro or -OH; and
R₆ is H, -CH₃, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF₃, nitro or -OH.

125. (new) A method of treating a 5HT_{2C} receptor associated disorder comprising administering to an individual in need of such treatment an effective amount of a compound according to claim 1, or a pharmaceutical composition according to claim 77.

Version with markings to show changes made.

1. (original) A compound of Formula (I):



wherein:

R₁ is H or C₁₋₈ alkyl;
R₂ is C₁₋₄ alkyl, -CH₂-O-C₁₋₄ alkyl, C₁₋₄ haloalkyl or CH₂OH; and
R₃, R₄, R₅ and R₆ are each independently H, C₁₋₄ alkyl, amino, cyano, halogen, C₁₋₄ haloalkyl, nitro or OH; or
a pharmaceutically acceptable salt, hydrate and solvate thereof;
provided that when R₂ is C₁₋₄ alkyl, -CH₂-O-C₁₋₄ alkyl, and CH₂OH then
R₃ and R₆ are not both hydrogen.

2. (original) The compound according to claim 1 wherein R₁ is H.
3. (original) The compound according to claim 1 wherein R₁ is C₁₋₈ alkyl.

Claims 4 to 8 have been canceled.

9. (amended) The compound according to ~~any one of claims~~ claim 1 to 8 wherein R₂ is C₁₋₄ alkyl.

10. (amended) The compound according to ~~any one of claims~~ claim 1 to 8 wherein R₂ is methyl.

Claims 11 to 13 have been canceled.

14. (amended) The compound according to ~~any one of claims~~ claim 1 to 8 wherein R₂ is C₁₋₄ haloalkyl.

Claim 15 has been canceled.

16. (amended) The compound according to ~~any one of claims~~ claim 1 to 15 wherein R_3 is H.

17. (amended) The compound according to ~~any one of claims~~ claim 1 to 15 wherein R_3 is C_{1-4} alkyl.

Claims 18 to 20 have been canceled.

21. (amended) The compound according to ~~any one of claims~~ claim 1 to 15 wherein R_3 is halogen.

Claims 22 to 25 have been canceled.

26. (amended) The compound according to ~~any one of claims~~ claim 1 to 15 wherein R_3 is C_{1-4} haloalkyl.

Claims 27 to 29 have been canceled.

30. (amended) The compound according to ~~any one of claims~~ claim 1 to 29 wherein R_4 is H.

31. (amended) The compound according to ~~any one of claims~~ claim 1 to 29 wherein R_4 is C_{1-4} alkyl.

Claims 32 to 34 have been canceled.

35. (amended) The compound according to ~~any one of claims~~ claim 1 to 29 wherein R_4 is halogen.

Claims 36 to 39 have been canceled.

40. (amended) The compound according to ~~any one of claims~~ claim 1 to 29 wherein R_4 is C_{1-4} haloalkyl.

Claims 41 to 43 have been canceled.

44. (amended) The compound according to ~~any one of claims~~ claim 1 to 43 wherein R_5 is H.

45. (amended) The compound according to ~~any one of claims~~ claim 1 to 43 wherein R_5 is C_{1-4} alkyl.

Claims 46 to 48 have been canceled.

49. (amended) The compound according to ~~any one of claims~~ claim 1 to 43 wherein R_5 is halogen.

Claims 50 to 53 have been canceled.

54. (amended) The compound according to ~~any one of claims~~ claim 1 to 43 wherein R_5 is C_{1-4} haloalkyl.

Claims 55 to 57 have been canceled.

58. (amended) The compound according to ~~any one of claims~~ claim 1 to 57 wherein R_6 is H.

59. (amended) The compound according to ~~any one of claims~~ claim 1 to 57 wherein R_6 is C_{1-4} alkyl.

Claims 60 to 62 have been canceled.

63. (amended) The compound according to ~~any one of claims~~ claim 1 to 57 wherein R_6 is halogen.

Claims 64 to 67 have been canceled.

68. (amended) The compound according to ~~any one of claims claim~~ 1 to 57 wherein R₆ is C₁₋₄ haloalkyl.

Claims 69 to 71 have been canceled.

72. (original) The compound of claim 1 selected from the group consisting of:
6,8-Dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
6-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
8-Chloro-9-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; and
8,9-Dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

73. (original) The compound of claim 1 that is 9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

74. (original) The compound of claim 1 selected from the group consisting of:
N-methyl-8,9-dichloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; and
N-methyl-9-bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

75. (amended) The compound according to ~~any one of claims claim~~ 1 to 74 wherein said compound is an *R* enantiomer.

76. (amended) The compound according to ~~any one of claims claim~~ 1 to 74 wherein said compound is an *S* enantiomer.

77. (amended) A pharmaceutical composition comprising a compound according to ~~any one of claims claim~~ 1 to 76 and a pharmaceutically acceptable carrier.

78. (amended) A method of modulating a 5HT_{2C} receptor comprising contacting said receptor with a therapeutically effective amount of a compound according to ~~any one of claims claim~~ 1 to 76.

79. (original) The method according to claim 78 wherein said compound is an agonist of said receptor.

80. (amended) A method of prophylaxis or treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus or sleep apnea comprising administering to an individual in need of such prophylaxis or treatment a therapeutically effective amount of a compound according to ~~any one of claims~~ claim 1 to 76 or a pharmaceutical composition according to claim 77.

81. (original) The method according to claim 80 wherein the disorders of the central nervous system are selected the group consisting of depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, Alzheimer disease, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.

82. (original) The method according to claim 81 wherein the disorder of the central nervous system is obesity.

Claim 83 has been canceled.

84. (original) The method according to claim 81 wherein the sexual dysfunction is Male erectile dysfunction.

Claims 85 to 89 have been canceled.

90. (amended) The method according to claim ~~89~~ 82 or 84 wherein said ~~mammal~~ individual is a human.

91. (amended) A method of decreasing food intake of an individual comprising administering to said individual a therapeutically effective amount of a compound according to ~~any one of claims~~ claim 1 to 76 or a pharmaceutical composition according to claim 77.

Claim 92 has been canceled.

93. (amended) The method according to claim ~~92~~91 wherein said ~~mammal~~individual is a human.

94. (amended) A method of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount of a compound according to ~~any one of claims~~ claim 1 to 76 or a pharmaceutical composition according to claim 77.

Claim 95 has been canceled.

96. (amended) The method according to claim ~~95~~94 wherein said ~~mammal~~individual is a human.

97. (amended) A method of controlling weight gain of an individual comprising administering to said individual suffering from weight control a therapeutically effective amount of a compound according to ~~any one of claims~~ claim 1 to 76 or a pharmaceutical composition according to claim 77.

Claim 98 has been canceled.

99. (amended) The method according to claim ~~98~~97 wherein said ~~mammal~~individual is a human.

Claims 100 to 103 have been canceled.

104. (amended) A method of producing a pharmaceutical composition comprising admixing at least one compound according to ~~any one of claims~~ claim 1 to 76 and a pharmaceutically acceptable carrier.

Claims 105 to 123 have been canceled.

124. (new) The compound according to claim 1 wherein:
- R₁ is H, methyl, ethyl, *n*-propyl, *iso*-propyl or *n*-butyl;
 - R₂ is methyl, ethyl, *iso*-propyl, *n*-butyl or -CF₃;
 - R₃ is H, -CH₃, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF₃, nitro or -OH;
 - R₄ is H, -CH₃, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF₃, nitro or -OH;
 - R₅ is H, -CH₃, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF₃, nitro or -OH; and
 - R₆ is H, -CH₃, amino, cyano, fluorine atom, chlorine atom, bromine atom, iodine atom, CF₃, nitro or -OH.
125. (new) A method of treating a 5HT_{2C} receptor associated disorder comprising administering to an individual in need of such treatment an effective amount of a compound according to claim 1, or a pharmaceutical composition according to claim 77.